除生长激素以外的促生长治疗的进展。
Progress on growth promoting therapies other than growth hormone.
出版信息
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Aug 1;51(4):515-520. doi: 10.3724/zdxbyxb-2022-0099.
Recombinant human growth hormone is a classical therapeutic drug for children with short stature. In recent years, as the mechanism of growth in children has been further explored, growth-promoting therapies other than growth hormone have made great progress. Recombinant human insulin-like growth factor (IGF)-1 is the main treatment for primary IGF-1 deficiency, and C-type natriuretic peptide (CNP) offers a therapeutic option for children with short stature due to chondrodysplasia. Growth hormone-releasing peptide analogues stimulate growth hormone release and may be used for growth-promoting therapy. In addition, gonadotropin-releasing hormone analogue (GnRHa) and aromatase inhibitors may delay the bone age in children and may be beneficial in improving final height. In this article, the research progress of growth-promoting therapies other than growth hormones is reviewed to provide more options for the clinical treatment of children with short stature.
重组人生长激素是治疗儿童矮小症的经典药物。近年来，随着儿童生长机制的进一步探索，除生长激素以外的促生长治疗也取得了很大的进展。重组人胰岛素样生长因子-1（IGF-1）是治疗原发性 IGF-1 缺乏症的主要药物，C 型利钠肽（CNP）为软骨发育不良导致的矮小症患儿提供了一种治疗选择。生长激素释放肽类似物可刺激生长激素释放，可用于促生长治疗。此外，促性腺激素释放激素类似物（GnRHa）和芳香化酶抑制剂可延缓儿童的骨龄，可能有利于改善最终身高。本文综述了除生长激素以外的促生长治疗的研究进展，为儿童矮小症的临床治疗提供更多选择。
Zotero 插件